1887

Abstract

Mice were immunized intramuscularly with free recombinant hepatitis C virus (HCV) NS3 (non-structural protein 3) protein, liposomes encapsulating rNS3 or rNS3 and CpG mixture, liposomes co-encapsulating rNS3 and CpG or liposomes co-encapsulating rNS3 and GpC. Liposomes co-encapsulating rNS3 and CpG induced a much higher titre of anti-HCV NS3 IgG and the dominant IgG subtype was IgG2a. Liposomes co-encapsulating rNS3 and GpC also induced high levels of anti-HCV NS3 IgG antibody, but the dominant IgG subtype was still IgG1, the same as in free HCV/NS3 immunized mice. Liposomes encapsulating rHCV NS3 and the mixture of rHCV NS3 and CpG did not increase the antibody response but switched the IgG subtype. A cytokine profile analysis revealed that the levels of Th1 cytokines in the mice immunized with liposomes co-encapsulating rHCV NS3 and CpG were significantly higher than in other mice while the levels of Th2 cytokine were significantly lower than in the mice immunized with naked rNS3. IL-12 in the mice immunized with liposome-NS3-CpG was significantly higher than in other mice. In conclusion, liposomes co-encapsulating HCV NS3 and CpG are a good candidate vaccine to induce strong Th1 immune responses against hepatitis C viruses.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.79896-0
2004-06-01
2020-12-03
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/6/vir851545.html?itemId=/content/journal/jgv/10.1099/vir.0.79896-0&mimeType=html&fmt=ahah

References

  1. Arribillaga L., de Cerio A. L., Sarobe P. 9 other authors 2002; Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 21:202–210 [CrossRef]
    [Google Scholar]
  2. Brazolot-Millan C. L. B., Weeratna R., Krieg A. M., Siegrist C. A., Davis H. L. 1998; CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A 95:15553–15558 [CrossRef]
    [Google Scholar]
  3. Brinster C., Muguet S., Lone Y. C., Boucreux D., Renard N., Fournillier A., Lemonnier F., Inchauspe G. 2001; Different hepatitis C virus nonstructural protein 3 (NS3)-DNA-expressing vaccines induce in HLA-A2·1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 34:1206–1217 [CrossRef]
    [Google Scholar]
  4. Brinster C., Chen M., Boucreux D., Paranhos-Baccala G., Liljestrom P., Lemmonier F., Inchauspe G. 2002; Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 83:369–381
    [Google Scholar]
  5. Carstens C. P. 2003; Use of tRNA-supplemented host strains for expression of heterologous genes in E. coli. Methods Mol Biol 205:225–233
    [Google Scholar]
  6. Cho J. H., Lee S. W., Sung Y. C. 1999; Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine 17:1136–1144 [CrossRef]
    [Google Scholar]
  7. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. 1989; Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362 [CrossRef]
    [Google Scholar]
  8. Chu R. S., Targoni O. S., Krieg A. M., Lehmann P. V., Harding C. V. 1997; CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623–1631 [CrossRef]
    [Google Scholar]
  9. Cohen J. 1999; The scientific challenge of hepatitis C. Science 285:26–30 [CrossRef]
    [Google Scholar]
  10. Cramp M. E., Rossol S., Chokshi S., Carucci P., Williams R., Naoumov N. V. 2000; Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118:346–355 [CrossRef]
    [Google Scholar]
  11. Davis H. L., Weeratna R., Waldschmidt T. J., Tygrett L., Schorr J., Krieg A. M. 1998; CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160:870–876
    [Google Scholar]
  12. Diepolder H. M., Zachoval R. M., Hoffmann R. M., Wierenga E. A., Santantonia T., Jung M. C., Eichenlaub D., Pape G. R. 1995; Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006–1007 [CrossRef]
    [Google Scholar]
  13. Diepolder H. M., Gerlach J.-T., Zachoval R. M. 9 other authors 1997; Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71:6011–6019
    [Google Scholar]
  14. Dow S. W., Fradkin L. G., Liggitt D. H., Willson A. P., Heath T. D., Potter T. A. 1999; Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 163:1552–1561
    [Google Scholar]
  15. Encke J., zu Putlitz J., Geissler M., Wands J. R. 1998; Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 161:4917–4923
    [Google Scholar]
  16. Frelin L., Alheim M., Chen A., Soderholm J., Rozell B., Barnfield C., Liljestrom P., Sallberg M. 2003; Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther 10:686–699 [CrossRef]
    [Google Scholar]
  17. Gordon E. J., Bhat R., Liu Q., Wang Y.-F., Tackney C., Prince A. M. 2000; Immune responses to hepatitis C virus structural and nonstructral proteins induced by plasmid DNA immunizations. J Infect Dis 181:42–50 [CrossRef]
    [Google Scholar]
  18. Hemmi H., Takeuchi O., Kawai T. 8 other authors 2000; A toll-like receptor recognizes bacterial DNA. Nature 408:740–745 [CrossRef]
    [Google Scholar]
  19. Jiao X., Wang R. Y.-H., Feng Z., Alter H. J., Shih J. W.-K. 2003; Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 of by cationic liposome encapsulated DNA immunization. Hepatology 37:452–460 [CrossRef]
    [Google Scholar]
  20. Jiao X., Wang R. Y.-H., Feng Z., Hu G., Alter H. J., Shih J. W.-K. 2004; DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response. J Viral Hepat 11:18–26 [CrossRef]
    [Google Scholar]
  21. Kane J. F. 1995; Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli . Curr Opin Biotechnol 6:494–500 [CrossRef]
    [Google Scholar]
  22. Kirby C., Gregoriadis G. 1984; Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 11:979–984
    [Google Scholar]
  23. Klinman D. M., Yi A. K., Beaucage S. L., Conover J., Krieg A. M. 1996; CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ . Proc Natl Acad Sci U S A 93:2879–2883 [CrossRef]
    [Google Scholar]
  24. Klinman D. M., Barnhart K. M., Conover J. 1999; CpG motifs as immune adjuvants. Vaccine 17:19–25 [CrossRef]
    [Google Scholar]
  25. Kourilsky P., Truffa-Bachi P. 2001; Cytokine fields and the polarization of the immune response. Trends Immunol 22:502–509 [CrossRef]
    [Google Scholar]
  26. Krieg A. M. 1996; Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol 4:73–76 [CrossRef]
    [Google Scholar]
  27. Krieg A. M. 1999; Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489107–116 [CrossRef]
    [Google Scholar]
  28. Krieg A. M. 2000; Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol 22:97–105 [CrossRef]
    [Google Scholar]
  29. Kusakabe K., Xin K. Q., Katoh H. 9 other authors 2000; The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 164:3102–3111 [CrossRef]
    [Google Scholar]
  30. Lanuti M., Rudginsky S., Force S. D. 7 other authors 2000; Cationic lipid: bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 60:2955–2963
    [Google Scholar]
  31. Lazdina U., Hultgren C., Frelin L. 8 other authors; 2001; Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J Gen Virol 82:1299–1308
    [Google Scholar]
  32. Li W. M., Bally M. B., Schutze-Redelmeier M. P. 2001; Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20:148–157 [CrossRef]
    [Google Scholar]
  33. McHutchison J. G., Gorden S. C., Schiff E. R. 7 other authors 1998; Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl J Med 339:1485–1492 [CrossRef]
    [Google Scholar]
  34. Moldoveanu Z., Love-Homan L., Huang W. Q., Krieg A. M. 1998; CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16:1216–1224 [CrossRef]
    [Google Scholar]
  35. Petsch D., Anspach F. B. 2000; Endotoxin removal from protein solutions. J Biotechnol 76:97–119 [CrossRef]
    [Google Scholar]
  36. Pisetsky D. S. 1996; Immune activation by bacterial DNA: a new genetic code. Immunity 5:303–310 [CrossRef]
    [Google Scholar]
  37. Poynard T., Marcellin P., Lee S. S. 8 other authors 1998; Randomised trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426–1432 [CrossRef]
    [Google Scholar]
  38. Rehermann B., Chisari F. V. 2000; Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 242:299–325
    [Google Scholar]
  39. Shevach E. M. 1994; ELISPOT assay to detect cytokine-secreting murine and human cells. In Current Protocols in Immunology vol 1pp. 6.19.1–6.19.8 Edited by Coligan J. E., Kruisbeek A. M., Margilies D. H., Shevach E. M. New York: Wiley;
    [Google Scholar]
  40. Shirota H., Sano K., Kikuchi T., Tamura G., Shirato K. 2000; Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol 164:5575–5582 [CrossRef]
    [Google Scholar]
  41. Shirota H., Sano K., Hirasawa N., Terui T., Ohuchi K., Hattori T., Shirato K., Tamura G. 2001; Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 167:66–74 [CrossRef]
    [Google Scholar]
  42. Simon B. E., Cornell K. A., Clark T. R., Chou S., Rosen H. R., Barry R. A. 2003; DNA vaccination protects mice against challenge with listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun 71:6372–6380 [CrossRef]
    [Google Scholar]
  43. Stratton K. R., Durch J. S., Lawrence R. S. 2000; Hepatitis C. In Vaccines for the 21st Century Washington, DC: National Academy Press;
    [Google Scholar]
  44. Sun S., Kishimoto H., Sprent J. 1998a; DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med 187:1145–1150 [CrossRef]
    [Google Scholar]
  45. Sun S., Zhang X., Tough D. F., Sprent J. 1998b; Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 188:2335–2342 [CrossRef]
    [Google Scholar]
  46. Tighe H., Takabayashi K., Schwartz D. 7 other authors 2000; Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 30:1939–1947 [CrossRef]
    [Google Scholar]
  47. Tsai S.-L., Liaw Y.-F., Chen M.-H., Huang C.-Y., Kuo G. C. 1997; Detection of type-2 like T-helper cells in hepatitis C virus infection: implication for hepatitis C chronicity. Hepatology 25:449–458 [CrossRef]
    [Google Scholar]
  48. Wedemeyer H., Gagneten S., Davis A., Bartenschlager R., Feinstone S., Rehermann B. 2001; Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 121:1158–1166 [CrossRef]
    [Google Scholar]
  49. Weiner G. J., Liu H. M., Wooldridge J. E., Dahle C. E., Krieg A. M. 1997; Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 94:10833–10837 [CrossRef]
    [Google Scholar]
  50. Whitmore M., Li S., Huang L. 1999; LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 6:1867–1875 [CrossRef]
    [Google Scholar]
  51. Zimmermann S., Egeter O., Hausmann S., Lipford G. B., Rocken M., Wagner H., Heeg K. 1998; CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160:3627–3630
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.79896-0
Loading
/content/journal/jgv/10.1099/vir.0.79896-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error